Alpha Cognition (ACOG) and Its Competitors Head to Head Comparison

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Alpha Cognition to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, dividends, risk, profitability and valuation.

Earnings and Valuation

This table compares Alpha Cognition and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.90
Alpha Cognition Competitors	$575.17 million	-$70.96 million	-1.94

Alpha Cognition’s rivals have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alpha Cognition and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Risk & Volatility

Alpha Cognition has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s rivals have a beta of -4.48, meaning that their average stock price is 548% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Alpha Cognition and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1971	5458	14069	304	2.58

Alpha Cognition presently has a consensus target price of $20.00, indicating a potential upside of 279.51%. As a group, “Biological products, except diagnostic” companies have a potential upside of 117.85%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Alpha Cognition is more favorable than its rivals.

Institutional and Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by company insiders. Comparatively, 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alpha Cognition beats its rivals on 8 of the 13 factors compared.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.